Bioharvest sciences strengthens balance sheet by $14.7 million with injection of $10.9 million gross proceeds and additional $3.8 million in debt reduction

Rehovot, israel--(newsfile corp. - september 22, 2025) - bioharvest sciences inc. (nasdaq: bhst) ("bioharvest" or the "company"), a biotechnology company pioneering its patented botanical synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the company's balance sheet with an additional $10.9 million in gross proceeds and a concurrent $3.8 million reduction in total debt. the following are the transactions which were executed subsequent to the company's published q2 2025 financial statements: successfully raised $5.8 million in incremental cash through the exercising of 898,277 warrants; raised an additional $5.1 million proceeds from the issuance of new convertible notes to multiple accredited investors that were subsequently converted into common shares; converted $1.8 million of pre-existing convertible notes into common shares; repaid $1.4 million of long-term debt following lenders exercising 214,915 warrants; and repaid $0.6 million of short-term debt via the issuance of shares the series of transactions were designed to deleverage the balance sheet and provide additional cash runway in support of the company's continued growth.
BHST Ratings Summary
BHST Quant Ranking